303 related articles for article (PubMed ID: 17295916)
1. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
2. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor immunotherapy with type-1 polarizing strategies.
Okada H
Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
[TBL] [Abstract][Full Text] [Related]
4. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
5. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
6. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
7. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
8. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans.
Caskey M; Lefebvre F; Filali-Mouhim A; Cameron MJ; Goulet JP; Haddad EK; Breton G; Trumpfheller C; Pollak S; Shimeliovich I; Duque-Alarcon A; Pan L; Nelkenbaum A; Salazar AM; Schlesinger SJ; Steinman RM; Sékaly RP
J Exp Med; 2011 Nov; 208(12):2357-66. PubMed ID: 22065672
[TBL] [Abstract][Full Text] [Related]
9. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis.
Wild JS; Hyde DM; Giri SN
Pharmacol Toxicol; 1994 Jul; 75(1):42-8. PubMed ID: 7526360
[TBL] [Abstract][Full Text] [Related]
10. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
[TBL] [Abstract][Full Text] [Related]
11. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
12. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
Fujita M; Zhu X; Ueda R; Sasaki K; Kohanbash G; Kastenhuber ER; McDonald HA; Gibson GA; Watkins SC; Muthuswamy R; Kalinski P; Okada H
Cancer Res; 2009 Feb; 69(4):1587-95. PubMed ID: 19190335
[TBL] [Abstract][Full Text] [Related]
13. Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC].
Chirigos MA; Papademetriou V; Bartocci A; Read E; Levy HB
Int J Immunopharmacol; 1981; 3(4):329-37. PubMed ID: 7333719
[TBL] [Abstract][Full Text] [Related]
14. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
Pessina GP; Muscettola M; Paulesu L; Bocci V
J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
[TBL] [Abstract][Full Text] [Related]
15. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
Salem ML; Kadima AN; Cole DJ; Gillanders WE
J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
[TBL] [Abstract][Full Text] [Related]
16. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
17. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant.
Marques RF; Gimenez AM; Caballero O; Simpson A; Salazar AM; Amino R; Godin S; Gazzinelli RT; Soares IS
Vaccine; 2024 Apr; 42(9):2394-2406. PubMed ID: 38448321
[TBL] [Abstract][Full Text] [Related]
19. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models.
Weng MT; Yang SF; Liu SY; Hsu YC; Wu MC; Chou HC; Chiou LL; Liang JD; Wang LF; Lee HS; Sheu JC
Pharmacol Res; 2023 Feb; 188():106646. PubMed ID: 36621619
[TBL] [Abstract][Full Text] [Related]
20. Interferon protects mice against inhalation anthrax.
Walberg K; Baron S; Poast J; Schwartz B; Izotova L; Pestka S; Peterson JW
J Interferon Cytokine Res; 2008 Oct; 28(10):597-601. PubMed ID: 18778201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
